Comorbidities in MS are associated with treatment intolerance and disability

Since the 1990s, an increasing number of disease-modifying therapies (DMTs) have been approved to treat multiple sclerosis (MS), bringing increasing choice and efficacy. With this has come greater complexity for patients in what should be a shared decision-making process, involving oral treatment or injections, with varying frequency of administration and need for laboratory monitoring. Risks are variable, and efficacy may be also. The complexity increases for women in childbearing years.

Source: Neurology - November 27, 2017 Category: Neurology Authors: McDonnell, G. V., Cohen, J. A. Tags: EDITORIALS Source Type: research